<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/72DFAE01-15C3-4469-97B2-362E8E48E591"><gtr:id>72DFAE01-15C3-4469-97B2-362E8E48E591</gtr:id><gtr:name>Simfonec</gtr:name><gtr:address><gtr:line1>Simfonec</gtr:line1><gtr:line2>Cass Business School</gtr:line2><gtr:line3>106 Bunhill Road</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>EC1Y 8TZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/004AADBE-9B0F-4E74-8526-BBD7E802176B"><gtr:id>004AADBE-9B0F-4E74-8526-BBD7E802176B</gtr:id><gtr:name>Pleiad</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AF7142B4-0AF5-4CCC-9A72-A5A3E45554F5"><gtr:id>AF7142B4-0AF5-4CCC-9A72-A5A3E45554F5</gtr:id><gtr:name>Dart Technologies</gtr:name><gtr:address><gtr:line1>71A Bell Street</gtr:line1><gtr:line2>Henley on Thames</gtr:line2><gtr:line3>Oxfordshire</gtr:line3><gtr:postCode>RG9 2BD</gtr:postCode><gtr:region>South East</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7A534411-6022-4B1F-BD15-9C5D7879113D"><gtr:id>7A534411-6022-4B1F-BD15-9C5D7879113D</gtr:id><gtr:name>WELLBEACH ASSOCIATES</gtr:name><gtr:address><gtr:line1>WELLBEACH ASSOCIATES</gtr:line1><gtr:line2>Wellbeach Farm</gtr:line2><gtr:line3>Rushton Spencer</gtr:line3><gtr:postCode>SK11 0QU</gtr:postCode><gtr:region>North West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D31C478D-680E-46CA-8A7F-8CD1698914FE"><gtr:id>D31C478D-680E-46CA-8A7F-8CD1698914FE</gtr:id><gtr:name>BioIndustry Association</gtr:name><gtr:address><gtr:line1>7th Floor Southside</gtr:line1><gtr:line2>105 Victoria Street</gtr:line2><gtr:postCode>SW1E 6QT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/09374414-6E77-4B09-ADC9-A85ACA97881E"><gtr:id>09374414-6E77-4B09-ADC9-A85ACA97881E</gtr:id><gtr:name>CMP THERAPEUTICS</gtr:name><gtr:address><gtr:line1>CMP THERAPEUTICS</gtr:line1><gtr:line2>BioPark</gtr:line2><gtr:line3>Broadwater Road</gtr:line3><gtr:line4>Welwyn Garden City</gtr:line4><gtr:line5>Herts</gtr:line5><gtr:postCode>AL7 3AX</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9718372D-9CFF-47AC-89AA-A59C0FD4C0C6"><gtr:id>9718372D-9CFF-47AC-89AA-A59C0FD4C0C6</gtr:id><gtr:name>NovaBiotics Ltd, UK</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C430EA89-4297-4955-8412-568540254AEA"><gtr:id>C430EA89-4297-4955-8412-568540254AEA</gtr:id><gtr:name>IDMOS PLC</gtr:name><gtr:address><gtr:line1>IDMOS PLC</gtr:line1><gtr:line2>Prospect Business Centre</gtr:line2><gtr:line3>The Technology Park</gtr:line3><gtr:line4>Dundee</gtr:line4><gtr:postCode>DD2 1SW</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/CD35D908-C2AF-4C14-9BC4-519C775CDB6E"><gtr:id>CD35D908-C2AF-4C14-9BC4-519C775CDB6E</gtr:id><gtr:name>City University London</gtr:name><gtr:department>Faculty of Management</gtr:department><gtr:address><gtr:line1>Northampton Square</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>EC1V 0HB</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CD35D908-C2AF-4C14-9BC4-519C775CDB6E"><gtr:id>CD35D908-C2AF-4C14-9BC4-519C775CDB6E</gtr:id><gtr:name>City University London</gtr:name><gtr:address><gtr:line1>Northampton Square</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>EC1V 0HB</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/004AADBE-9B0F-4E74-8526-BBD7E802176B"><gtr:id>004AADBE-9B0F-4E74-8526-BBD7E802176B</gtr:id><gtr:name>Pleiad</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AF7142B4-0AF5-4CCC-9A72-A5A3E45554F5"><gtr:id>AF7142B4-0AF5-4CCC-9A72-A5A3E45554F5</gtr:id><gtr:name>Dart Technologies</gtr:name><gtr:address><gtr:line1>71A Bell Street</gtr:line1><gtr:line2>Henley on Thames</gtr:line2><gtr:line3>Oxfordshire</gtr:line3><gtr:postCode>RG9 2BD</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D31C478D-680E-46CA-8A7F-8CD1698914FE"><gtr:id>D31C478D-680E-46CA-8A7F-8CD1698914FE</gtr:id><gtr:name>BioIndustry Association</gtr:name><gtr:address><gtr:line1>7th Floor Southside</gtr:line1><gtr:line2>105 Victoria Street</gtr:line2><gtr:postCode>SW1E 6QT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/09374414-6E77-4B09-ADC9-A85ACA97881E"><gtr:id>09374414-6E77-4B09-ADC9-A85ACA97881E</gtr:id><gtr:name>CMP THERAPEUTICS</gtr:name><gtr:address><gtr:line1>CMP THERAPEUTICS</gtr:line1><gtr:line2>BioPark</gtr:line2><gtr:line3>Broadwater Road</gtr:line3><gtr:line4>Welwyn Garden City</gtr:line4><gtr:line5>Herts</gtr:line5><gtr:postCode>AL7 3AX</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9718372D-9CFF-47AC-89AA-A59C0FD4C0C6"><gtr:id>9718372D-9CFF-47AC-89AA-A59C0FD4C0C6</gtr:id><gtr:name>NovaBiotics Ltd, UK</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/72DFAE01-15C3-4469-97B2-362E8E48E591"><gtr:id>72DFAE01-15C3-4469-97B2-362E8E48E591</gtr:id><gtr:name>Simfonec</gtr:name><gtr:address><gtr:line1>Simfonec</gtr:line1><gtr:line2>Cass Business School</gtr:line2><gtr:line3>106 Bunhill Road</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>EC1Y 8TZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7A534411-6022-4B1F-BD15-9C5D7879113D"><gtr:id>7A534411-6022-4B1F-BD15-9C5D7879113D</gtr:id><gtr:name>WELLBEACH ASSOCIATES</gtr:name><gtr:address><gtr:line1>WELLBEACH ASSOCIATES</gtr:line1><gtr:line2>Wellbeach Farm</gtr:line2><gtr:line3>Rushton Spencer</gtr:line3><gtr:postCode>SK11 0QU</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C430EA89-4297-4955-8412-568540254AEA"><gtr:id>C430EA89-4297-4955-8412-568540254AEA</gtr:id><gtr:name>IDMOS PLC</gtr:name><gtr:address><gtr:line1>IDMOS PLC</gtr:line1><gtr:line2>Prospect Business Centre</gtr:line2><gtr:line3>The Technology Park</gtr:line3><gtr:line4>Dundee</gtr:line4><gtr:postCode>DD2 1SW</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5787377B-2A74-4ED4-86DF-68ECDBBCDE65"><gtr:id>5787377B-2A74-4ED4-86DF-68ECDBBCDE65</gtr:id><gtr:name>PRESCOT AND LEMAN EXECUTIVE SEARCH LTD</gtr:name><gtr:address><gtr:line1>PRESCOT AND LEMAN EXECUTIVE SEARCH LTD</gtr:line1><gtr:line2>One Prescott Street</gtr:line2><gtr:line3>2nd Floor</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>E1 8RJ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AA376F09-E37C-40C0-BA9D-0787895020FC"><gtr:id>AA376F09-E37C-40C0-BA9D-0787895020FC</gtr:id><gtr:name>DART TECHNOLOGY UK LTD</gtr:name><gtr:address><gtr:line1>DART TECHNOLOGY UK LTD</gtr:line1><gtr:line2>Beechwood</gtr:line2><gtr:line3>2 Clathymore Drive</gtr:line3><gtr:line4>Perth</gtr:line4><gtr:postCode>PH1 1NW</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D84655F0-D384-4104-8AE9-4A3711571622"><gtr:id>D84655F0-D384-4104-8AE9-4A3711571622</gtr:id><gtr:name>PLEIAD DEVICES</gtr:name><gtr:address><gtr:line1>PLEIAD DEVICES</gtr:line1><gtr:line2>Balmoral Suite, Royal British House</gtr:line2><gtr:line3>Leonard Street</gtr:line3><gtr:line4>Perth</gtr:line4><gtr:postCode>PH2 8HA</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D4F6DC86-AC39-4FD8-AF1F-5F5B5B1086C1"><gtr:id>D4F6DC86-AC39-4FD8-AF1F-5F5B5B1086C1</gtr:id><gtr:name>NOVABIOTICS LTD</gtr:name><gtr:address><gtr:line1>NOVABIOTICS LTD</gtr:line1><gtr:line2>Cruickshank Building</gtr:line2><gtr:line3>Craibstone</gtr:line3><gtr:line4>Aberdeen</gtr:line4><gtr:postCode>AB21 9TR</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1D3E7ADC-DAAF-4F14-AF43-A255EE45A219"><gtr:id>1D3E7ADC-DAAF-4F14-AF43-A255EE45A219</gtr:id><gtr:name>Arrow Therapeutics</gtr:name><gtr:address><gtr:line1>Britannia House</gtr:line1><gtr:line2>7 Trinity Street</gtr:line2><gtr:postCode>SE1 1DA</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/CF9AB1DE-730D-402E-A9D6-89BCE1C15393"><gtr:id>CF9AB1DE-730D-402E-A9D6-89BCE1C15393</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Nightingale</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/4E250487-FBC9-4284-BA99-0F32EF61CDC7"><gtr:id>4E250487-FBC9-4284-BA99-0F32EF61CDC7</gtr:id><gtr:firstName>Charles</gtr:firstName><gtr:surname>Baden Fuller</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=EP%2FE037208%2F1"><gtr:id>759550B9-5D6E-4815-94FA-DAA6FF85BCCD</gtr:id><gtr:title>Financial and Organisational Innovation in UK Biotech</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/E037208/1</gtr:grantReference><gtr:abstractText>Biotechnology firms in the UK increasingly access funds from financial markets, such as the Alternative Investment Market (AIM), rather than traditional venture capital (VC) firms because they are dissatisfied with the poor advice and lack of funding support from traditional VCs. In addition, many of these firms have adopted innovative business models that speed up product development processes by using highly experienced boards of directors and advisors to access external knowledge. Because previous research has focused on funding from venture capitalists, at present little is known about what sorts of business models are most appropriate for this new form of funding and how these boards and advisors are motivated by new forms of financing. This research seeks to (a) understand how these changes impact firm performance and (b) develop innovative management tools to help firms set up a powerful board, and show how that board should operate and how it should access AIM, other non-VC sources of money, and specialist advisors.Previous research on biotechnology start-ups typically draws on a model extrapolated from US experience in the 1980s, where the stages of firm development are linked to types of funding: seed funding (including university technology funds); business angels; V-C (venture capital) followed by IPO (initial public offering on financial markets) or trade sales. While the model may have once been useful, it is increasingly inappropriate for the UK as some firms are short-circuiting stages of the cycle, while others are developing alternative routes. The fact that AIM is now larger than VC as a total supply of finance to UK technology in general and to biotechnology in particular emphasises how the UK has moved towards a distinctive market-based biotechnology funding model.Under this new model, university spin-outs and other start-up firms exploit strong intellectual property over their technology to go straight from founding to forming a highly-skilled board of directors. These boards develop credentials impressive enough for a medium sized public-listed-company very early and are used to access levels of external, specialist professional knowledge normally associated with well established firms. Firms adopting this model rely much more heavily on high powered boards and specialists for managerial advice (rather than VCs and university technology transfer offices). It has been assumed that this knowledge outsourcing strategy could not work as start-up firms lack the resources to attract such high-level advisors. However, preparatory research and first hand experience (one of the proposers is on several biotechnology boards) suggests that the practice is increasingly important. The two strands of research within the project - funding innovations and new managerial knowledge arrangements - are closely connected. It seems clear that using high-powered boards and high levels of external advisors makes a young firm more attractive for floatation on public markets, enabling them to draw on much larger sources of funding. While the opportunity to be involved in public visible, fast growth firms attracts the high-powered boards in the first place. By better understanding these changes, and developing management tools to assit firms this project will asssit the development of high-tech biotech firms within the UK economy and extend the application of innovative forms of financing.</gtr:abstractText><gtr:fund><gtr:end>2010-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2007-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>751336</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>IDMOS PLC</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>IDMOS PLC</gtr:description><gtr:id>107B0CE0-8FF1-49AC-B51D-FB0768A9C4EF</gtr:id><gtr:outcomeId>b9c9da1ab9c9da2e-1</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wellbeach Associates</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>WELLBEACH ASSOCIATES</gtr:description><gtr:id>BA65381F-1774-4DD2-8F22-E7C32DE61FFD</gtr:id><gtr:outcomeId>b9c9eee2b9c9eef6-1</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>CMP Therapeutics</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CMP THERAPEUTICS</gtr:description><gtr:id>4D716B6B-AFD5-490B-900F-454172A5FD16</gtr:id><gtr:outcomeId>b9c9cdf4b9c9ce08-1</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Arrow Therapeutics</gtr:department><gtr:description>Arrow Therapeutics Ltd</gtr:description><gtr:id>524E9386-F02E-49C1-AF93-C4F83D2485A0</gtr:id><gtr:outcomeId>b9c9955ab9c99578-1</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pleiad</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PLEIAD DEVICES</gtr:description><gtr:id>8C72BD10-9FAC-489A-818A-09D65AE24DD1</gtr:id><gtr:outcomeId>b9c971a6b9c971c4-1</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>NovaBiotics Ltd, UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>NOVABIOTICS LTD</gtr:description><gtr:id>9A4640AF-F5DC-4DD8-B8F3-403D83367812</gtr:id><gtr:outcomeId>b9c9e3d4b9c9e3e8-1</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dart Technologies</gtr:collaboratingOrganisation><gtr:country>Bangladesh, People's Republic of</gtr:country><gtr:description>Dart Technologies</gtr:description><gtr:id>F88C14BB-953A-4908-BD96-1F44A99D8790</gtr:id><gtr:outcomeId>b9c99136b9c9914a-1</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Simfonec</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Simfonec</gtr:description><gtr:id>31D47E77-AC68-4834-B91C-DBF45DFE05B8</gtr:id><gtr:outcomeId>b9c9f2cab9c9f2e8-1</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>BioIndustry Association</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>BioIndustry Association</gtr:description><gtr:id>77501153-8755-48F1-A1C5-0BB744CFA132</gtr:id><gtr:outcomeId>b9c885c0b9c885de-1</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>We devoted considerable effort researching management issues and we found that many companies relied on their boards to act as an extension of the top management team, rather than as monitors and occasional advisors. This challenges current academic thinking and much policy advice, and we have developed advanced tool kits on the topic that have been road tested. 
We organised 5 conferences; attended by 222 people from industry and the financial community, and 49 policy advisors from BISS, Treasury, BIA, NESTA, BVCA, Bio-Wednesday (London First). We integrated the projects research results and presented them in a series of workshops at GSK attended by over 100 senior and junior staff from across the company in the summer of 2010. 

Title Date Location Policy Industry Academic Totals
Toolkits For Boards 28/10/2007 Cass 5 9 6 20
BVCA &amp;amp; NESTA Workshops 30/4 &amp;amp; 6/5 2007 Cass 11 16 13 40
BVCA &amp;amp; NESTA Report Launch 02/7/2009 NESTA 16 74 6 96
Bio-Wednesday: Growing Bio-Business* 10/3/2010 Cass 17 123 35 175
GSK June 2010 GSK 100 ** 
Totals 49 322 60 431
* with London Biotechnology Network
** Approximate 

Our research work allowed us to get very close to companies such as GSK, Pfizer and Astra Zeneca as well as many smaller UK and European R&amp;amp;D biotechnology firms.</gtr:description><gtr:firstYearOfImpact>2007</gtr:firstYearOfImpact><gtr:id>7C1C441B-2B58-4CFA-B988-4FE6E9BA4FE3</gtr:id><gtr:impactTypes><gtr:impactType>Economic,Policy &amp; public services</gtr:impactType></gtr:impactTypes><gtr:outcomeId>56d01595441035.13321573</gtr:outcomeId><gtr:sector>Education,Financial Services, and Management Consultancy,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>SUMMARY OF KEY FINDINGS

We collected and analysed in a novel fashion data on all the 247 UK drug discovery and development firms founded between 1980 and 2008. Most are specialists exploiting UK research on therapeutics. The project also examined in more detail the activities of some 23 firms and their supporting partners to create a richer picture of the challenges that firms face. The project also engaged extensively with the whole community of policy makers, supporting firms (directly and through our advisory board of entrepreneurs and financiers), and academic partners.



We found that (smaller and newer) UK drug development firms are challenged in managing growth and capturing value, particularly as profitable exits are difficult. For example, in the period only 13 firms managed to sell for cash to a large pharmaceutical company; but many more merged to ensure survival rather than properly exit. Firms financed themselves in various ways and some 40% did not use formal venture capital.



Business Model Virtual Integrated

Speed Faster Slower

Costs Can be cheaper: locate low cost Fixed costs and commitment

Flexibility Up front flexibility in choice of partner Lots of on going flexibility within

Risks High but some flexibility Problem of commitment

IP Strategy Requires extra care Reasonably Clear 



Identifying and developing appropriate Business Models was a key issue: there are distinct choices, one of the most important of which is whether to be virtual or integrated in research. We explored how this choice influences and is influenced by both funding and by the drug development trajectory. 



We also used our project to advance theoretical knowledge on Business Models and organised a special issue with internationally acclaimed academics from Harvard, Wharton and other major business schools on the topic (Long Range Planning, April 2010). We have developed and are now refining business model tool kits. 





Gaining funding is a key challenge for UK high-technology firms. With &amp;pound;100K co-funding from NESTA-BVCA, the team produced the &amp;quot;Thin Markets&amp;quot; report that attracted national media comment (R4 Today programme, FT etc). We identified a series of funding challenges that growth orientated firms face at every stage on account of insufficiently developed venture capital markets and lack of experienced UK management. We developed 'time cost of capital' tool kits for companies based on this research and a range of policy implications.



We devoted considerable effort researching management issues and we found that many companies relied on their boards to act as an extension of the top management team, rather than as monitors and occasional advisors. This challenges current academic thinking and much policy advice, and we have developed advanced tool kits on the topic that have been road tested. 



 Board composition in sample of early stage firms: 

 Board Size Average

Outside directorships Technical development (count) Business development (count) Corporate finance (count) Entrepreneurial knowledge (count)

NOVA 8 19.8 3 1 3 1

AOX 6 33.8 2 1 2 1

PHY 9 25.6 1 2 2 3

AUV 10 15.8 1 3 3 1

ID 7 31.1 2 3 1 1

AIR 4 15.5 1 1 1 1

CYTO 7 19.9 2 2 2 1

BLUE 4 33.3 1 1 1 1</gtr:description><gtr:exploitationPathways>DISSEMINATION

We used an advisory board to guide us in our work, led by John Pool serial entrepreneur associated with 35 health care companies.



Name Role Company

John K Pool, Chairman Entrepreneur Many including Novabiotics

Dr Fraser Campbell Venture Capitalist (V.C) Private Co.

Neil Crabb V.C. Sigma Capital Group PLC

Hugh Gardner Lawyer Marriottharrison 

Malcolm J Gillies Lawyer Shepherd &amp;amp; Wedderburn

Jean Hamilton Economist Jean Hamilton Ltd

Jonathan Lloyd-Hirst V.C. Ernst&amp;amp; Young

Michael Martin V.C. Anvil Partners

Drs Folker Pieterse V.C. Private Co.

Geoffrey Thomson V.C. Braveheart Investment Group PLC

Giles Vardey Entrepreneur PLUS Markets (UK) PLC (Chairman) 



We organised 5 conferences; attended by 222 people from industry and the financial community, and 49 policy advisors from BISS, Treasury, BIA, NESTA, BVCA, Bio-Wednesday (London First). We integrated the projects research results and presented them in a series of workshops at GSK attended by over 100 senior and junior staff from across the company in the summer of 2010. 



Title Date Location Policy Industry Academic Totals

Toolkits For Boards 28/10/2007 Cass 5 9 6 20

BVCA &amp;amp; NESTA Workshops 30/4 &amp;amp; 6/5 2007 Cass 11 16 13 40

BVCA &amp;amp; NESTA Report Launch 02/7/2009 NESTA 16 74 6 96

Bio-Wednesday: Growing Bio-Business* 10/3/2010 Cass 17 123 35 175

GSK June 2010 GSK 100 ** 

Totals 49 322 60 431

* with London Biotechnology Network

** Approximate 



Our research work allowed us to get very close to companies such as GSK, Pfizer and Astra Zeneca as well as many smaller UK and European R&amp;amp;D biotechnology firms.



COMPANIES Private &amp;amp; Emerging companies UK Listed Companies Major International Pharma

 Interviewed in-depth research 18 5 3

Cases released 5 1 




 Through 5 academic workshops held at Cass, we have engaged 116 international and 75 UK scholars. We also gave more than 40 presentations at international meetings and university seminars, including a number of keynote conference presentations on the project work. 



Theme UK academics International academics Others Total

Scientific and Managerial Knowledge 25-26 June 07 Cass 12 6 0 18

Scientific and Managerial Knowledge 17-18 Dec 07 Cass 14 11 3 28

Scientific and Managerial Knowledge 25-26 June 08 Cass 23 55 2 80

Business Models 15 -17 Dec 08 Cass 14 31 0 45

Strategy Workshop 16 -18 Dec 09 Cass 12 13 1 26

Totals 75 116 6 197



As said above, during the project, we obtained a &amp;pound;100K grant from NESTA-BVCA in 2008-9 to examine the early stage venture capital provision in the UK and the role played by 'hybrid' VC funds.</gtr:exploitationPathways><gtr:id>9020581E-14A6-40B5-A1DA-6E408778B81E</gtr:id><gtr:outcomeId>r-1685740949.293357477819fd6</gtr:outcomeId><gtr:sectors><gtr:sector>Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>190D18C3-0ADE-4DB4-BA1D-52B216ED5236</gtr:id><gtr:title>Shareholder returns and the exploration dilemma: R&amp;amp;D announcements by biotechnology firms</gtr:title><gtr:parentPublicationTitle>Research Policy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/629d526c9b2ab4296296253f023d2908"><gtr:id>629d526c9b2ab4296296253f023d2908</gtr:id><gtr:otherNames>Charles Baden Fuller (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:outcomeId>m_14218910871376b534</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3342C57-F56B-49EA-B8CD-2822C68594E0</gtr:id><gtr:title>Knowledge integration using product R&amp;amp;D outsourcing in biotechnology</gtr:title><gtr:parentPublicationTitle>Research Policy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf20f1e28b23a015311de331d58609f0"><gtr:id>cf20f1e28b23a015311de331d58609f0</gtr:id><gtr:otherNames>Kamuriwo D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>585d457532cb60.59473698</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8229D5A3-8587-4C13-B986-B4583AAFD595</gtr:id><gtr:title>The Influence of Technological Knowledge Base and Organizational Structure on Technology Collaboration</gtr:title><gtr:parentPublicationTitle>Journal of Management Studies</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f5ff2310b21823fdc45326aba6a7d2d"><gtr:id>6f5ff2310b21823fdc45326aba6a7d2d</gtr:id><gtr:otherNames>Zhang J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>563343d9f169c4.26839199</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FAA7C5E3-BEB5-4AED-A238-7091B50A2F5D</gtr:id><gtr:title>From Recipe to Dinner: Business Model Portfolios in the European Biopharmaceutical Industry</gtr:title><gtr:parentPublicationTitle>Long Range Planning</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1291eb39704893c92f16262b6dd2f1b"><gtr:id>f1291eb39704893c92f16262b6dd2f1b</gtr:id><gtr:otherNames>Sabatier V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>doi_53cffffff9a79185</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0BF6DA13-F211-4B86-9B0D-33D009D48108</gtr:id><gtr:title>Resolving the Tensions between Monitoring, Resourcing and Strategizing: Structures and Processes in High Technology Venture Boards</gtr:title><gtr:parentPublicationTitle>Long Range Planning</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f5ff2310b21823fdc45326aba6a7d2d"><gtr:id>6f5ff2310b21823fdc45326aba6a7d2d</gtr:id><gtr:otherNames>Zhang J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>doi_53cffffff9caec0f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7DF6ACE5-7A42-48BE-81F1-6382D324BF35</gtr:id><gtr:title>Business Models as Models</gtr:title><gtr:parentPublicationTitle>Long Range Planning</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0a6907f3d02ef332cb53b6b23bf221f"><gtr:id>e0a6907f3d02ef332cb53b6b23bf221f</gtr:id><gtr:otherNames>Baden-Fuller C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>doi_53cffffff9b1f9df</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2C07EB2-95EB-41A1-86E7-23DC959694D4</gtr:id><gtr:title>Shareholder returns and the exploration-exploitation dilemma: R&amp;amp;D announcements by biotechnology firms</gtr:title><gtr:parentPublicationTitle>Research Policy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74fdf7e8e82cb5fbdc85a38cb16a8a60"><gtr:id>74fdf7e8e82cb5fbdc85a38cb16a8a60</gtr:id><gtr:otherNames>Mc Namara P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:outcomeId>doi_53d0080086bb4501</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2668ECC5-7AE5-4D21-9210-92316C5B9EBB</gtr:id><gtr:title>Technological paradigms: past, present and future</gtr:title><gtr:parentPublicationTitle>Industrial and Corporate Change</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4cec5772ce686cb8217fea57d4d671b0"><gtr:id>4cec5772ce686cb8217fea57d4d671b0</gtr:id><gtr:otherNames>von Tunzelmann N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:outcomeId>doi_53d04604698851a9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>870D9081-C715-41BA-A8F0-E87A59E7CF4A</gtr:id><gtr:title>From Funding Gaps to Thin Markets</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/138f29594b2d67574f4e4b190c4a2d98"><gtr:id>138f29594b2d67574f4e4b190c4a2d98</gtr:id><gtr:otherNames>P Nightingale</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:outcomeId>m_232584400413aa2432</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FC79524-00E7-4C0B-8E8B-A01F7C0BC859</gtr:id><gtr:title>Who is My Partner and How Do We Dance? Technological Collaboration and Patenting Speed in US Biotechnology</gtr:title><gtr:parentPublicationTitle>British Journal of Management</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/668d889ab184c9c7f91c631abbbd3e34"><gtr:id>668d889ab184c9c7f91c631abbbd3e34</gtr:id><gtr:otherNames>Al-Laham A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>doi_53d067067640c170</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E5231864-0DDA-4945-9576-09CBF2094912</gtr:id><gtr:title>Organizing for innovation: towards successful translational research.</gtr:title><gtr:parentPublicationTitle>Trends in biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b51de92cbf2fab954f6ad9a54ecbb40c"><gtr:id>b51de92cbf2fab954f6ad9a54ecbb40c</gtr:id><gtr:otherNames>West W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0167-7799</gtr:issn><gtr:outcomeId>doi_53d00d00d507283a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ADE98F14-4F1E-4F11-93B1-9F58E39AB494</gtr:id><gtr:title>Buying big into biotech: scale, financing, and the industrial dynamics of UK biotech, 1980-2009</gtr:title><gtr:parentPublicationTitle>Industrial and Corporate Change</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7657d64d45de5fb5ed078c6b246e5713"><gtr:id>7657d64d45de5fb5ed078c6b246e5713</gtr:id><gtr:otherNames>Hopkins M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>56334474c5d214.24451846</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C37D89C-EBCA-4D49-87E9-7AB7F72D3281</gtr:id><gtr:title>Hybrid Organizational Mechanisms in Inter-organizational Multiproduct Innovation Arrangements</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d401865db8fd7f1f2afbc34eb54d44d3"><gtr:id>d401865db8fd7f1f2afbc34eb54d44d3</gtr:id><gtr:otherNames>D Kamuriwo</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:outcomeId>m_787619529413dc651e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE65FB1E-D9D4-4A87-A78C-A192E5703F68</gtr:id><gtr:title>Editorial</gtr:title><gtr:parentPublicationTitle>Long Range Planning</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0a6907f3d02ef332cb53b6b23bf221f"><gtr:id>e0a6907f3d02ef332cb53b6b23bf221f</gtr:id><gtr:otherNames>Baden-Fuller C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>doi_53cffffff9bae8cc</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/E037208/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>5E9AA4EC-49E3-4D6A-B545-79DA07CE39E0</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Management &amp; Business Studies</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>6A482B09-D749-4443-8AF0-654984FCE91D</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Manufact. Business Strategy</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>2E2E80C2-8D14-44CE-A971-37A9ACC4B244</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Manufact. Enterprise Ops&amp; Mgmt</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>